Despite the availability of advanced chemotherapeutic treatments, colorectal carcinoma (CRC) remains a major cause of cancer morbidity and mortality, representing the third most common type of cancer in men and the second most common in women worldwide.1,2 Several biomarkers have been investigated for relevance to CRC prognosis, including RAS, BRAF mutations and MSI status. Here, BRAF is linked to cancer.